Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ:TIL)

8.080 +0.300 (+3.86%)
Streaming Delayed Price Updated: 1:55 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Instil Bio, Inc.

< Previous 1 2 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells 
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
News headline image
NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc. ↗
San Diego, CA -- (SBWIRE) -- 02/10/2023 -- Certain directors of Instil Bio, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.